跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
SANDOZ DEFERASIROX - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
SANDOZ DEFERASIROX
Authorized
STANDARD
SANDOZ DEFERASIROX
Sandoz Canada, Inc.
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
2781a00c21818173
Company
Sandoz Canada, Inc.
Type
Standard
Approval Details
Approval Id
2781a00c21818173
Drug Approval Canada Name
SANDOZ DEFERASIROX
Product Name
SANDOZ DEFERASIROX
Status
Marketed
Status Date
2017-07-04
Original Market Date
2017-07-04
Din
02464462
Drug Class
Human
Dosage Form
Tablet For Suspension
Route Of Administration
Oral
Schedule
Prescription
Ahfs
64:00.00
Atc Original
V03AC03 DEFERASIROX
Atc Name
v 03 ac 03
Aig Number
0151733002
Company Name
Sandoz Canada, Inc.
Company Address
4600 Rue Armand-Frappier, Saint-Hubert, Quebec, Canada, J3Z 1G5
Company Detail Path
/organization/sandoz-canada-inc
Company Information
Pharmaceutical Company Name
Sandoz Canada, Inc.
Country Name
Canada
Website
http://www.sandoz.ca
Active Ingredients
DEFERASIROX
250 MG
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
2781a00c21818173
Type
Standard
Back to Health Canada Approvals